GPER G-1 Development Group is a drug discovery and development company with the primary goal of advancing novel drug candidates that modulate the G protein-coupled Estrogen Receptor (GPER). The lead drug candidate is G-1 (Tespria™), a GPER agonist to treat obesity through weight loss, and to reverse diabetes and pre-diabetes. Researchers at the University of New Mexico have identified a G protein-coupled Estrogen Receptor (GPER) as a novel therapeutic target for obesity and diabetes. Patented compounds binding GPER do not interact with the ERα/β estrogen receptors and so do not exhibit estrogenic feminizing effects. The GPER G-1 Development Group is focused on developing this proprietary technology into small molecule drug compounds, including G-1 (a GPER-selective agonist), and G15 and G36 (GPER-selective antagonists). Currently identified indications for the drug candidates include obesity, diabetes, cardiovascular diseases, kidney diseases, fibrosis and bacterial infection.
GPER G-1 Development Group is presenting as part of the NIH Innovation Zone.